

10/590549

IAP9 Rec'd PCT/PTO 23 AUG 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re International Application of OHNO, Hiroyuki et al.

International Serial No.: PCT/JP2005/002988

International Filing date: February 24, 2005

For: Novel Imidazolium Compound

VERIFICATION OF TRANSLATION

Honorable Commissioner of Patents and Trademarks
Washington D.C. 20231

Sirs:

MOCHIZUKI, Shiro residing at T & T Bldg., 8-21, Tomihisa-cho, Shinjuku-ku, Tokyo, Japan, declares:

(1) that he knows well both Japanese and English languages;

(2) that he translated the above-identified International Application from Japanese to English;

(3) that the attached English translation is a true and correct translation of Amendment under Article 19 PCT of the above-identified International Application to the best of his knowledge and belief; and


(4) that all statements made of his own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements are made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 USC 1001, and that such false statements may jeopardize the validity of the application or any patent issuing thereon.

5th July 2006
Date

Shiro Mochizuki
MOCHIZUKI, Shiro

[Claims in Written Amendment]

[1] (Amended) An imidazolium compound represented by Formula (I) below:




in which, R_1 , R_2 , R_3 , and R_4 independently denote a hydrogen atom, an optionally substituted alkyl group having 1 to 10 carbon atoms, an optionally substituted cycloalkyl group having 3 to 10 carbon atoms, an optionally substituted alkenyl group having 2 to 10 carbon atoms, or an optionally substituted aryl group having 6 to 10 carbon atoms, and X^- is Cl^- , Br^- , I^- , BF_4^- , PF_6^- , $CF_3SO_3^-$, or $(CF_3SO_2)_2N^-$, with the proviso that when R_1 is an alkyl group having 1 to 2 carbon atoms, X^- is BF_4^- , PF_6^- , $CF_3SO_3^-$, or $(CF_3SO_2)_2N^-$, and a case in which R_2 to R_4 are hydrogen atoms, R_1 is an allyl group, and X^- is Br^- is excluded.

[2] The imidazolium compound according to Claim 1, wherein R_1 is preferably an alkyl group having 4 to 8 carbon atoms or an alkenyl group having 2 to 4 carbon atoms.

[3] The imidazolium compound according to either Claim 1 or

2, wherein R_1 is an allyl group.

[4] A solvent comprising an imidazolium compound represented by Formula (I) below:



in which, R_1 , R_2 , R_3 , and R_4 independently denote a hydrogen atom, an optionally substituted alkyl group having 1 to 10 carbon atoms, an optionally substituted cycloalkyl group having 3 to 10 carbon atoms, an optionally substituted alkenyl group having 2 to 10 carbon atoms, or an optionally substituted aryl group having 6 to 10 carbon atoms, and X^- is Cl^- , Br^- , I^- , BF_4^- , PF_6^- , $CF_3SO_3^-$, or $(CF_3SO_2)_2N^-$.

[5] An electrolyte material comprising the imidazolium compound according to Claim 4, wherein X^- is BF_4^- , PF_6^- , $CF_3SO_3^-$, or $(CF_3SO_2)_2N^-$.